greenovation preclinical data

In a mouse model of Fabry’s disease, single IV injections of 0.3, 1 and 3 mg/kg moss-aGal dose-dependently reduced globotriaosylceramide (GL-3) levels in the kidney, heart and liver. Additionally, mo...